The Atlanta-based medical weight loss company has big plans for Tampa Bay, including a large new facility and substantial ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

"Everyone is talking about personalized medicine, but no one is defining it," said Chris Spears, CEO and founder of OrderlyMeds. "At OrderlyMeds, we're going further. We're not just providing ...

OrderlyMeds, a provider of compounded versions of GLP-1 weight loss drugs, including Eli Lilly’s (NYSE:LLY) tirzepatide, said on Friday that a cease-and-desist letter sent by the pharma giant would ...

Morningstar brands and products Company Portfolio ...